Corcept Therapeutics (CORT) Stock Forecast, Price & News

Corcept Therapeutics (NASDAQ:CORT) Frequently Asked Questions

Is Corcept Therapeutics a buy right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Corcept Therapeutics in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Corcept Therapeutics stock.
View analyst ratings for Corcept Therapeutics or view top-rated stocks.

When is Corcept Therapeutics' next earnings date?

Corcept Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for Corcept Therapeutics.

How were Corcept Therapeutics' earnings last quarter?

Corcept Therapeutics Incorporated (NASDAQ:CORT) posted its earnings results on Thursday, May, 5th. The biotechnology company reported $0.20 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.23 by $0.03. The biotechnology company earned $93.70 million during the quarter, compared to analysts' expectations of $103.23 million. Corcept Therapeutics had a trailing twelve-month return on equity of 24.23% and a net margin of 29.42%. The firm's revenue for the quarter was up 18.0% compared to the same quarter last year. During the same period in the previous year, the company earned $0.18 EPS.
View Corcept Therapeutics' earnings history.

What guidance has Corcept Therapeutics issued on next quarter's earnings?

Corcept Therapeutics updated its FY 2022 earnings guidance on Monday, May, 16th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $400.00 million-$430.00 million, compared to the consensus revenue estimate of $413.85 million.

What price target have analysts set for CORT?

4 brokers have issued twelve-month price objectives for Corcept Therapeutics' stock. Their forecasts range from $29.00 to $30.00. On average, they anticipate Corcept Therapeutics' share price to reach $29.67 in the next twelve months. This suggests a possible upside of 51.7% from the stock's current price.
View analysts' price targets for Corcept Therapeutics or view top-rated stocks among Wall Street analysts.

Who are Corcept Therapeutics' key executives?

Corcept Therapeutics' management team includes the following people:

• Dr. Joseph K. Belanoff M.D., Co-Founder, Pres, CEO & Director (Age 65, Pay $1.69M)
• Mr. Atabak Mokari, CFO & Treasurer (Age 45, Pay $687.98k)
• Dr. Hazel Hunt Ph.D., Chief Scientific Officer
• Mr. Sean Maduck, Pres of Corcept Endocrinology (Age 45, Pay $828.83k) (LinkedIn Profile)
• Mr. Gary Charles Robb, Chief Bus. Officer & Sec. (Age 59, Pay $900.08k) (LinkedIn Profile)
• Mr. Joseph Douglas Lyon, Chief Accounting Officer (Age 43) (LinkedIn Profile)
• Dr. Christopher Shayne James M.D., Director of Investor Relations
• Ms. Amy Flood, Chief HR & Communications Officer
• Donald E. Laferle, Sr. VP
• Dr. William Guyer Pharm.D., Chief Devel. Officer

What is Joseph K. Belanoff's approval rating as Corcept Therapeutics' CEO?

6 employees have rated Corcept Therapeutics CEO Joseph K. Belanoff on Glassdoor.com. Joseph K. Belanoff has an approval rating of 100% among Corcept Therapeutics' employees. This puts Joseph K. Belanoff in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Corcept Therapeutics' key competitors?

Some companies that are related to Corcept Therapeutics include Johnson & Johnson (JNJ), Pfizer (PFE), Eli Lilly and (LLY), AbbVie (ABBV), Merck & Co., Inc. (MRK), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Royalty Pharma (RPRX), Horizon Therapeutics Public (HZNP), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), Pacira BioSciences (PCRX), Supernus Pharmaceuticals (SUPN), Nektar Therapeutics (NKTR) and Endo International (ENDP).
View all of CORT's competitors.

What other stocks do shareholders of Corcept Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Corcept Therapeutics investors own include Micron Technology (MU), NVIDIA (NVDA), Advanced Micro Devices (AMD), AbbVie (ABBV), CA (CA), Alibaba Group (BABA), BlackRock (BLK), Inovio Pharmaceuticals (INO), Pfizer (PFE) and Activision Blizzard (ATVI).

What is Corcept Therapeutics' stock symbol?

Corcept Therapeutics trades on the NASDAQ under the ticker symbol "CORT."

Who are Corcept Therapeutics' major shareholders?

Corcept Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include BlackRock Inc. (14.52%), Vanguard Group Inc. (9.82%), Renaissance Technologies LLC (7.31%), Ingalls & Snyder LLC (6.50%), Federated Hermes Inc. (4.46%) and State Street Corp (3.21%). Company insiders that own Corcept Therapeutics stock include Daniel N Swisher Jr, G Leonard Baker Jr, G Leonard Baker, Jr, Gary Charles Robb, Joseph Douglas Lyon and Sean Maduck.
View institutional ownership trends for Corcept Therapeutics.

Which major investors are selling Corcept Therapeutics stock?

CORT stock was sold by a variety of institutional investors in the last quarter, including Arrowstreet Capital Limited Partnership, Vanguard Group Inc., Renaissance Technologies LLC, TD Asset Management Inc., Northern Trust Corp, Jane Street Group LLC, Martingale Asset Management L P, and Bank of New York Mellon Corp. Company insiders that have sold Corcept Therapeutics company stock in the last year include Daniel N Swisher Jr, Gary Charles Robb, and Sean Maduck.
View insider buying and selling activity for Corcept Therapeutics or view top insider-selling stocks.

Which major investors are buying Corcept Therapeutics stock?

CORT stock was bought by a variety of institutional investors in the last quarter, including SG Americas Securities LLC, Great Lakes Advisors LLC, BlackRock Inc., Boston Trust Walden Corp, Hillsdale Investment Management Inc., Royce & Associates LP, Ingalls & Snyder LLC, and Parallel Advisors LLC. Company insiders that have bought Corcept Therapeutics stock in the last two years include G Leonard Baker Jr, and G Leonard Baker, Jr.
View insider buying and selling activity for Corcept Therapeutics or or view top insider-buying stocks.

How do I buy shares of Corcept Therapeutics?

Shares of CORT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Corcept Therapeutics' stock price today?

One share of CORT stock can currently be purchased for approximately $19.55.

How much money does Corcept Therapeutics make?

Corcept Therapeutics has a market capitalization of $2.08 billion and generates $365.98 million in revenue each year. The biotechnology company earns $112.51 million in net income (profit) each year or $0.909990 on an earnings per share basis.

How many employees does Corcept Therapeutics have?

Corcept Therapeutics employs 238 workers across the globe.

When was Corcept Therapeutics founded?

Corcept Therapeutics was founded in 1998.

What is Corcept Therapeutics' official website?

The official website for Corcept Therapeutics is www.corcept.com.

How can I contact Corcept Therapeutics?

Corcept Therapeutics' mailing address is 149 COMMONWEALTH DRIVE, MENLO PARK CA, 94025. The biotechnology company can be reached via phone at (650) 327-3270, via email at [email protected], or via fax at 650-327-3218.